Cannabidiol (CBD) Capsules (Tilray CBD 25)
Cannabidiol (CBD) Capsules risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Tilray CBD 25, Entoura CBD Caps.
Cannabidiol (CBD) Capsules (brand names: Tilray CBD 25, Entoura CBD Caps) is classified as Moderate risk (5 risk points) by AllMeds. It is a S4 medication under the TGA in Australia.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Moderate (5 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
Risk Profile
Regulatory and Compliance Guidance
When Cannabidiol (CBD) Capsules appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Clinical Evidence
- Cannabidiol for chronic pain: A systematic review and meta-analysis (2022)
Systematic review finding limited but emerging evidence for CBD in chronic pain. Most studies have small sample sizes and short duration.
Peer-reviewed systematic review — notes evidence limitations
- SIRA NSW Medication Management — Cannabis Medicines Section (2023)
SIRA guidance on medicinal cannabis in workers comp. Requires prior authorisation, TGA SAS approval, and evidence of failed conventional treatment.
NSW workers comp regulator — directly relevant to AllMeds use case
- TGA: Access to Medicinal Cannabis — SAS Category 5 Pathway (2024)
CBD products accessed via TGA SAS Category 5 (Authorised Prescriber) or SAS-B notification. Not registered on ARTG. Prescriber must be authorised.
TGA regulatory framework for access
- Guidance for the Use of Medicinal Cannabis — TGA (2024)
TGA clinical guidance on prescribing medicinal cannabis including CBD products. Covers indications, dosing, monitoring.
Official TGA guidance
- RACP Position Statement on Medicinal Cannabis (2023)
RACP supports access via clinical trials and SAS but notes evidence is limited for most chronic pain indications.
Peak Australian medical body
Need to assess this medication across your caseload?
Run a full risk assessment including Cannabidiol (CBD) Capsules interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.